News Image

Investors should take notice of NYSE:MRK—it offers a great deal for the fundamentals it presents.

By Mill Chart

Last update: Feb 5, 2024

Discover MERCK & CO. INC. (NYSE:MRK), an undervalued stock highlighted by our stock screener. NYSE:MRK showcases solid financial health and profitability while maintaining an appealing valuation. We'll explore the details.

Deciphering NYSE:MRK's Valuation Rating

ChartMill employs its own Valuation Rating system for all stocks. This score, ranging from 0 to 10, is determined by evaluating different valuation factors, including price to earnings and free cash flow, both in absolute terms and relative to the market and industry. NYSE:MRK has earned a 7 for valuation:

  • Compared to the rest of the industry, the Price/Earnings ratio of MRK indicates a somewhat cheap valuation: MRK is cheaper than 79.70% of the companies listed in the same industry.
  • MRK's Price/Forward Earnings ratio is rather cheap when compared to the industry. MRK is cheaper than 83.66% of the companies in the same industry.
  • MRK is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 21.44, which is the current average of the S&P500 Index.
  • Based on the Enterprise Value to EBITDA ratio, MRK is valued a bit cheaper than 78.71% of the companies in the same industry.
  • MRK's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MRK is cheaper than 81.19% of the companies in the same industry.
  • MRK's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • MRK has a very decent profitability rating, which may justify a higher PE ratio.
  • MRK's earnings are expected to grow with 89.34% in the coming years. This may justify a more expensive valuation.

How do we evaluate the Profitability for NYSE:MRK?

Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NYSE:MRK has achieved a 7:

  • With an excellent Return On Assets value of 4.32%, MRK belongs to the best of the industry, outperforming 89.11% of the companies in the same industry.
  • MRK has a Return On Equity of 11.17%. This is amongst the best in the industry. MRK outperforms 90.59% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 8.70%, MRK belongs to the top of the industry, outperforming 88.12% of the companies in the same industry.
  • MRK has a Profit Margin of 7.77%. This is amongst the best in the industry. MRK outperforms 87.62% of its industry peers.
  • MRK's Operating Margin of 15.53% is amongst the best of the industry. MRK outperforms 85.64% of its industry peers.
  • MRK has a better Gross Margin (73.09%) than 81.68% of its industry peers.
  • In the last couple of years the Gross Margin of MRK has grown nicely.

Evaluating Health: NYSE:MRK

Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NYSE:MRK has achieved a 5 out of 10:

  • An Altman-Z score of 4.62 indicates that MRK is not in any danger for bankruptcy at the moment.
  • MRK has a better Altman-Z score (4.62) than 79.21% of its industry peers.
  • MRK has a debt to FCF ratio of 2.65. This is a good value and a sign of high solvency as MRK would need 2.65 years to pay back of all of its debts.
  • MRK has a better Debt to FCF ratio (2.65) than 90.59% of its industry peers.

How We Gauge Growth for NYSE:MRK

ChartMill employs its own Growth Rating system for all stocks. This score, ranging from 0 to 10, is derived by evaluating different growth factors, such as EPS and revenue growth, taking into account both past performance and future projections. NYSE:MRK has earned a 4 for growth:

  • Based on estimates for the next years, MRK will show a very strong growth in Earnings Per Share. The EPS will grow by 50.72% on average per year.
  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More Decent Value stocks can be found in our Decent Value screener.

Check the latest full fundamental report of MRK for a complete fundamental analysis.

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

MERCK & CO. INC.

NYSE:MRK (4/23/2024, 7:14:02 PM)

After market: 127.05 +0.17 (+0.13%)

126.88

-0.06 (-0.05%)

MRK News

News Image8 hours ago - InvestorPlaceInvestor Alert: Prepare for the Market Crash With These 3 Stocks

These are the low-beta and attractively valued stocks to buy for a market crash as they represent companies with strong fundamentals.

News Image10 hours ago - InvestorPlace3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge

These are the undervalued pharmaceutical stocks to buy as they have a deep clinical pipeline which will driven earnings and cash flow growth.

News Image5 days ago - Merck Canada Inc.Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and

/CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab),...

News Image7 days ago - InvestorPlaceComing FDA Approvals Could Send These 3 Drug Stocks Soaring

When it comes to drug stocks, FDA approval can bring years or even decades of steady, high-margin revenue.

News Image7 days ago - InvestorPlace3 Dow Stocks to Buy Now: Q2 Edition

Although the idea of Dow stocks to buy now is patently boring, that could be a positive attribute amid the current backdrop.

News Image9 days ago - The Motley FoolBetter Growth Play: Merck or The Vanguard Growth Index Fund?

Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?

News Image10 days ago - The Motley FoolMerck Paid $208 Million to Stop Its Drugs From Working. Here's Why That's Bullish.

Being able to stop a drug's unwanted effects could lead to a larger market share.

News Image12 days ago - The Motley Fool1 New Green Flag for Moderna and Merck Stock

There's a new reason to believe that their joint projects are going well.

News Image12 days ago - InvestorPlace7 A-Rated Aggressive Biotech Stocks to Bet On in 2024

We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades.

News Image12 days ago - Market News VideoSee Which Of The Latest 13F Filers Holds Merck & Co
News Image13 days ago - InvestorPlaceThe $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today

Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.

News Image13 days ago - ChartmillWhen you look at NYSE:MRK, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

MERCK & CO. INC. (NYSE:MRK): good value for what you're paying.

MRK Links
Follow us for more